Moleculin Announces Independent Study Validates Annamycin’s Ability to Target Lung Localized Tumors

HOUSTON, Oct. 21, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced results from an independent laboratory validating internal animal studies showing the ability of Annamycin to target lung localized tumors.

The release as fetched from its publisher. moleculin.com ↗